The impact of autoimmune diseases on the incidence and prognosis of cutaneous malignant melanoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 9, 2007, Pages 1840-1844

  Kaae, Jeanette ^a   Wohlfahrt, Jan ^a   Boyd, Heather A ^a   Wulf, Hans Christian ^b   Biggar, Robert J ^c   Melbye, Mads ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

ARTICLE; AUTOIMMUNE DISEASE; CANCER INCIDENCE; CANCER MORTALITY; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; SKIN TUMOR;

AUTOIMMUNITY; COHORT STUDIES; HUMANS; INCIDENCE; INTERFERON ALFA-2B; MELANOMA; NETHERLANDS; PROGNOSIS; SKIN NEOPLASMS;

EID: 34548851698     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0459     Document Type: Article

References (21)

1. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon α-2b in high-riskmelan oma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-58.
2. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon α-2b adjuvant therapy of high-riskresecte d cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
3. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80.
4. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
5. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-18.
6. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996;19:81-4.
7. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988;318:1557-63.
8. Scalzo S, Gengaro A, Boccoli G, et al. Primary hypothyroidism associated with interleukin-2 and interferon α-2 therapy of melanoma and renal carcinoma. Eur J Cancer 1990;26:1152-6.
9. Krouse RS, Royal RE, Heywood G, et al. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother Emphasis Tumor Immunol 1995;18:272-8.
10. Weijl NI, Van der HD, Brand A, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993;11:1376-83.
11. Chan C, O'Day J. Melanoma-associated retinopathy: does autoimmunity prolong survival? Clin Experiment Ophthalmol 2001;29:235-8.
12. Becker JC, Winkler B, Klingert S, Brocker EB. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 1994;73:1621-4.
13. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24- 37.
14. Malig C. The civil registration system in Denmark. 66, 1-6. 1996. Technical Papers. Ref Type: Generic.
15. Storm HH. The Danish Cancer Registry, a self-reporting national cancer registration system with elements of active data collection. IARC Sci Publ 1991;220-36.
16. Lipsky PE. Autoimmunity and autoimmune diseases. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine, 15th ed. New York: McGraw-Hill; 2001. p. 1839-43.
17. Haynes BF, Fauci AS. Introduction to the immune system. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., editors. Harrison's principles of internal medicine, 14th ed. New York: McGraw-Hill; 1998. p. 1753-76.
18. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7.
19. Koh LK, Greenspan FS, Yeo PP. Interferon-α induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997;7:891-6.
20. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43.
21. Pedersen M, Klarlund M, Jacobsen S, Svendsen AJ, Frisch M. Validity of rheumatoid arthritis diagnoses in the Danish National Patient Registry. Eur J Epidemiol 2004;19:1097-103.